Loading…
Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas
Background Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aim...
Saved in:
Published in: | Annals of surgical oncology 2023-12, Vol.30 (13), p.8621-8630 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13 |
---|---|
cites | cdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13 |
container_end_page | 8630 |
container_issue | 13 |
container_start_page | 8621 |
container_title | Annals of surgical oncology |
container_volume | 30 |
creator | Miyata, Yoichi Yonamine, Naoto Fujinuma, Ibuki Tsunenari, Takazumi Takihata, Yasuhiro Hakoda, Hiroyuki Nakazawa, Akiko Iwasaki, Toshimitsu Einama, Takahiro Togashi, Junichi Tsujimoto, Hironori Ueno, Hideki Beck, Yoshifumi Kishi, Yoji |
description | Background
Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs.
Methods
Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS
small
and TS
large
groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum
P
value approach for the risk of R1 resection.
Results
TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS
large
than TS
small
group, in both R- (
n
= 35, 37% versus
n
= 294, 19%;
P
= 0.011) and BR-PDAC (
n
= 89, 37% versus
n
= 27, 15%;
P
= 0.030). Overall survival was significantly better in the TS
small
than TS
large
group in R-PDAC (38.2 versus 12.1 months;
P
< 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months;
P
= 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC.
Conclusion
Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC. |
doi_str_mv | 10.1245/s10434-023-14219-3 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2860404420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2860404420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</originalsourceid><addsrcrecordid>eNp9kV1PFTEQhhsjETj6B7wwTbzhZqHTj_24RFQgIYEgXjdtdw5Zstse210j_HoHD6LxwqRJm5ln3pnOy9hbEIcgtTkqILTSlZCqAi2hq9QLtgeGQrpu4SW9Rd1WnazNLtsv5U4IaJQwr9iuamrTykbtsR_n08aFmac1v8qYNpjdPHxHfrNMKfMvwwPyFCmVbmMqQ3nkrrFgmJ0fkbvY8w8p95jHIeLfmSsXQ0bSCvzjQrGRH_cYU3A5DDFNrrxmO2s3FnzzdK_Y18-fbk7OqovL0_OT44sqqMbMlaTxaVjw2qyD9B22QEeh8C2CMaA8_bVvVCcVLaPulYLQgQ_et01TI6gVO9jqbnL6tmCZ7TSUgOPoIqalWNnWQgutpSD0_T_oXVpypOmIamswUtHOVkxuqZBTKRnXdpOHyeV7C8I--mK3vljyxf7yxSoqevckvfgJ--eS30YQoLZAoVS8xfyn939kfwKlF5fV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886152327</pqid></control><display><type>article</type><title>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</title><source>Springer Nature</source><creator>Miyata, Yoichi ; Yonamine, Naoto ; Fujinuma, Ibuki ; Tsunenari, Takazumi ; Takihata, Yasuhiro ; Hakoda, Hiroyuki ; Nakazawa, Akiko ; Iwasaki, Toshimitsu ; Einama, Takahiro ; Togashi, Junichi ; Tsujimoto, Hironori ; Ueno, Hideki ; Beck, Yoshifumi ; Kishi, Yoji</creator><creatorcontrib>Miyata, Yoichi ; Yonamine, Naoto ; Fujinuma, Ibuki ; Tsunenari, Takazumi ; Takihata, Yasuhiro ; Hakoda, Hiroyuki ; Nakazawa, Akiko ; Iwasaki, Toshimitsu ; Einama, Takahiro ; Togashi, Junichi ; Tsujimoto, Hironori ; Ueno, Hideki ; Beck, Yoshifumi ; Kishi, Yoji</creatorcontrib><description>Background
Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs.
Methods
Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS
small
and TS
large
groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum
P
value approach for the risk of R1 resection.
Results
TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS
large
than TS
small
group, in both R- (
n
= 35, 37% versus
n
= 294, 19%;
P
= 0.011) and BR-PDAC (
n
= 89, 37% versus
n
= 27, 15%;
P
= 0.030). Overall survival was significantly better in the TS
small
than TS
large
group in R-PDAC (38.2 versus 12.1 months;
P
< 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months;
P
= 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC.
Conclusion
Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-023-14219-3</identifier><identifier>PMID: 37658273</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenocarcinoma ; Carcinoma, Pancreatic Ductal - surgery ; Humans ; Medical prognosis ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Oncology ; Pancreas ; Pancreatectomy - adverse effects ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - surgery ; Pancreatic Tumors ; Prognosis ; Retrospective Studies ; Surgery ; Surgical Oncology ; Survival ; Tumors</subject><ispartof>Annals of surgical oncology, 2023-12, Vol.30 (13), p.8621-8630</ispartof><rights>Society of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Society of Surgical Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</citedby><cites>FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</cites><orcidid>0000-0002-5201-4477</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37658273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyata, Yoichi</creatorcontrib><creatorcontrib>Yonamine, Naoto</creatorcontrib><creatorcontrib>Fujinuma, Ibuki</creatorcontrib><creatorcontrib>Tsunenari, Takazumi</creatorcontrib><creatorcontrib>Takihata, Yasuhiro</creatorcontrib><creatorcontrib>Hakoda, Hiroyuki</creatorcontrib><creatorcontrib>Nakazawa, Akiko</creatorcontrib><creatorcontrib>Iwasaki, Toshimitsu</creatorcontrib><creatorcontrib>Einama, Takahiro</creatorcontrib><creatorcontrib>Togashi, Junichi</creatorcontrib><creatorcontrib>Tsujimoto, Hironori</creatorcontrib><creatorcontrib>Ueno, Hideki</creatorcontrib><creatorcontrib>Beck, Yoshifumi</creatorcontrib><creatorcontrib>Kishi, Yoji</creatorcontrib><title>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs.
Methods
Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS
small
and TS
large
groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum
P
value approach for the risk of R1 resection.
Results
TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS
large
than TS
small
group, in both R- (
n
= 35, 37% versus
n
= 294, 19%;
P
= 0.011) and BR-PDAC (
n
= 89, 37% versus
n
= 27, 15%;
P
= 0.030). Overall survival was significantly better in the TS
small
than TS
large
group in R-PDAC (38.2 versus 12.1 months;
P
< 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months;
P
= 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC.
Conclusion
Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.</description><subject>Adenocarcinoma</subject><subject>Carcinoma, Pancreatic Ductal - surgery</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Pancreas</subject><subject>Pancreatectomy - adverse effects</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>Pancreatic Tumors</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Tumors</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kV1PFTEQhhsjETj6B7wwTbzhZqHTj_24RFQgIYEgXjdtdw5Zstse210j_HoHD6LxwqRJm5ln3pnOy9hbEIcgtTkqILTSlZCqAi2hq9QLtgeGQrpu4SW9Rd1WnazNLtsv5U4IaJQwr9iuamrTykbtsR_n08aFmac1v8qYNpjdPHxHfrNMKfMvwwPyFCmVbmMqQ3nkrrFgmJ0fkbvY8w8p95jHIeLfmSsXQ0bSCvzjQrGRH_cYU3A5DDFNrrxmO2s3FnzzdK_Y18-fbk7OqovL0_OT44sqqMbMlaTxaVjw2qyD9B22QEeh8C2CMaA8_bVvVCcVLaPulYLQgQ_et01TI6gVO9jqbnL6tmCZ7TSUgOPoIqalWNnWQgutpSD0_T_oXVpypOmIamswUtHOVkxuqZBTKRnXdpOHyeV7C8I--mK3vljyxf7yxSoqevckvfgJ--eS30YQoLZAoVS8xfyn939kfwKlF5fV</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Miyata, Yoichi</creator><creator>Yonamine, Naoto</creator><creator>Fujinuma, Ibuki</creator><creator>Tsunenari, Takazumi</creator><creator>Takihata, Yasuhiro</creator><creator>Hakoda, Hiroyuki</creator><creator>Nakazawa, Akiko</creator><creator>Iwasaki, Toshimitsu</creator><creator>Einama, Takahiro</creator><creator>Togashi, Junichi</creator><creator>Tsujimoto, Hironori</creator><creator>Ueno, Hideki</creator><creator>Beck, Yoshifumi</creator><creator>Kishi, Yoji</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5201-4477</orcidid></search><sort><creationdate>20231201</creationdate><title>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</title><author>Miyata, Yoichi ; Yonamine, Naoto ; Fujinuma, Ibuki ; Tsunenari, Takazumi ; Takihata, Yasuhiro ; Hakoda, Hiroyuki ; Nakazawa, Akiko ; Iwasaki, Toshimitsu ; Einama, Takahiro ; Togashi, Junichi ; Tsujimoto, Hironori ; Ueno, Hideki ; Beck, Yoshifumi ; Kishi, Yoji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>Carcinoma, Pancreatic Ductal - surgery</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Pancreas</topic><topic>Pancreatectomy - adverse effects</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>Pancreatic Tumors</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyata, Yoichi</creatorcontrib><creatorcontrib>Yonamine, Naoto</creatorcontrib><creatorcontrib>Fujinuma, Ibuki</creatorcontrib><creatorcontrib>Tsunenari, Takazumi</creatorcontrib><creatorcontrib>Takihata, Yasuhiro</creatorcontrib><creatorcontrib>Hakoda, Hiroyuki</creatorcontrib><creatorcontrib>Nakazawa, Akiko</creatorcontrib><creatorcontrib>Iwasaki, Toshimitsu</creatorcontrib><creatorcontrib>Einama, Takahiro</creatorcontrib><creatorcontrib>Togashi, Junichi</creatorcontrib><creatorcontrib>Tsujimoto, Hironori</creatorcontrib><creatorcontrib>Ueno, Hideki</creatorcontrib><creatorcontrib>Beck, Yoshifumi</creatorcontrib><creatorcontrib>Kishi, Yoji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyata, Yoichi</au><au>Yonamine, Naoto</au><au>Fujinuma, Ibuki</au><au>Tsunenari, Takazumi</au><au>Takihata, Yasuhiro</au><au>Hakoda, Hiroyuki</au><au>Nakazawa, Akiko</au><au>Iwasaki, Toshimitsu</au><au>Einama, Takahiro</au><au>Togashi, Junichi</au><au>Tsujimoto, Hironori</au><au>Ueno, Hideki</au><au>Beck, Yoshifumi</au><au>Kishi, Yoji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>30</volume><issue>13</issue><spage>8621</spage><epage>8630</epage><pages>8621-8630</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs.
Methods
Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS
small
and TS
large
groups according to a TS cutoff value determined for each of R- and BR-PDAC using the minimum
P
value approach for the risk of R1 resection.
Results
TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS
large
than TS
small
group, in both R- (
n
= 35, 37% versus
n
= 294, 19%;
P
= 0.011) and BR-PDAC (
n
= 89, 37% versus
n
= 27, 15%;
P
= 0.030). Overall survival was significantly better in the TS
small
than TS
large
group in R-PDAC (38.2 versus 12.1 months;
P
< 0.001), but comparable between the two groups in BR-DPAC (21.2 versus 22.7 months;
P
= 0.363). Multivariate analysis revealed TS > 35 mm as an independent predictor of worse survival in patients with R-PDAC.
Conclusion
Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>37658273</pmid><doi>10.1245/s10434-023-14219-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5201-4477</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1068-9265 |
ispartof | Annals of surgical oncology, 2023-12, Vol.30 (13), p.8621-8630 |
issn | 1068-9265 1534-4681 |
language | eng |
recordid | cdi_proquest_miscellaneous_2860404420 |
source | Springer Nature |
subjects | Adenocarcinoma Carcinoma, Pancreatic Ductal - surgery Humans Medical prognosis Medicine Medicine & Public Health Multivariate analysis Oncology Pancreas Pancreatectomy - adverse effects Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - surgery Pancreatic Tumors Prognosis Retrospective Studies Surgery Surgical Oncology Survival Tumors |
title | Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A01%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Preoperative%20Tumor%20Size%20on%20Prognosis%20of%20Resectable%20and%20Borderline%20Resectable%20Pancreatic%20Ductal%20Adenocarcinomas&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Miyata,%20Yoichi&rft.date=2023-12-01&rft.volume=30&rft.issue=13&rft.spage=8621&rft.epage=8630&rft.pages=8621-8630&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-023-14219-3&rft_dat=%3Cproquest_cross%3E2860404420%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-29267651b45fc2b9e81e813e0b8e15513b468d739230436d331c91bcbb8776e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2886152327&rft_id=info:pmid/37658273&rfr_iscdi=true |